secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENANTA PHARMACEUTICALS INC (ENTA)
CIK:        0001177648
Form:       8-K
Filed at:   2026-06-23T21:28:13+00:00
Accession:  0001193125-26-279803
Event type: litigation
Sentiment:  negative
Materiality: 0.80
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Enanta loses Federal Circuit appeal; Paxlovid patent claims invalidated
-----------------------------------------------------------------------

- Federal Circuit affirmed Dec 2024 summary judgment, ruling claims of U.S. Patent No. 11,358,953 invalid.
- Patent covered Pfizer's COVID-19 antiviral Paxlovid (nirmatrelvir; ritonavir).
- Enanta had sought damages for infringement; appeal loss eliminates potential royalty stream.
- Decision issued on June 23, 2026 by the U.S. Court of Appeals for the Federal Circuit.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1177648/000119312526279803/0001193125-26-279803-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1177648/000119312526279803/d133783d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-279803

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer